MSD has applied to the Federal
Court of Australia for an injunction
in relation to plans by Apotex to
market a generic version of MSD’s
Nasonex (mometasone furate)
aquesous nasal spray.
MSD said that Apotex plans to
start supplying a generic version of
the product from Sep this year,
which is claimed to be an
infringement of MSD’s patent on
the product which expires in 2015.
“MSD plans to vigorously defend
its rights,” the company said, with
the court expected to consider the
application in the coming weeks.The above article was sent to subscribers in Pharmacy Daily's issue from 04 Jul 12 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 04 Jul 12
THE stark health inequalities between Australians living in regional and metro areas have been highlighted in a new report from The Royal Flying Doctor Service (RFDS).
AN “AI explosion” is sweeping Australia’s healthcare sector, signalling the arrival of an “extraordinary era of medicine”, according to a new report from CSIRO.
THE Australian and New Zealand College of Advanced Pharmacy (ANZCAP) has celebrated the 1,000th pharmacist to complete its pharmacy recognition program (PD 24 Nov 2023).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.